¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ À¯¹æ¾Ï ȯÀÚ¿¡°Ô º£Å¸-Â÷´ÜÁ¦ »ç¿ë (Beta-Blocker Use) Ä¡·áÈ¿°ú
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

               À¯¹æ¾Ï ȯÀÚ¿¡°Ô º£Å¸-Â÷´ÜÁ¦ »ç¿ë (Beta-Blocker Use) Ä¡·áÈ¿°ú

 

ÀÓ»óÁú¹®

º£Å¸ Â÷´ÜÁ¦ »ç¿ë (Beta-Block Use)ÀÌ À¯¹æ¾Ï ȯÀÚÀÇ »ç¸ÁÀ²°ú Àç¹ß °¨¼Ò¿¡ È¿°úÀûÀԴϱî?

±Ù°Å±â¹Ý´äº¯

º£Å¸ Â÷´ÜÁ¦´Â Àü¹ÝÀûÀÎ »ç¸Á (overall deaths, ODs), ¾Ï ƯÁ¤ »ç¸Á (cancer-specific deaths, CSDs) ¶Ç´Â Àç¹ß (recurrences)°ú °ü·ÃÇÏ¿© À¯ÀÍÇÏÁö ¸øÇÏ¿´À½À» º¸°íÇÏ¿´½À´Ï´Ù.

¼­ÁöÁ¤º¸

Is Beta-Blocker Use Beneficial in Breast Cancer?  A Meta-Analysis (2017), Oncology, 2017; 92 ( 5 ) :264-268, DOI: 10.1159/000455143.

Áúº´Æ¯¼º

º£Å¸ Â÷´ÜÁ¦¸¦ Åõ¿©¹Þ°í ÀÖ´Â À¯¹æ¾Ï ȯÀÚ

(beta-blocker users and non-beta-blocker users)

¿¬±¸¼³°è

¸ÞŸºÐ¼® (Meta-Analysis)

¿¬±¸´ë»ó

18,118¸íÀÇ À¯¹æ¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÔ

Æò°¡ÁöÇ¥

Àü¹ÝÀû »ç¸Á(Overall deaths, ODs)

¾ÏƯÁ¤ »ç¸Á(Cancer-specific deaths (CSDs)

Àç¹ß(recurrences)

»ó¼¼¼³¸í

18,118 ¸íÀÇ È¯ÀÚ¸¦ Æ÷ÇÔÇÑ 6 °³ÀÇ ¿¬±¸°¡ ºÐ¼®¿¡ ·£´ý È¿°ú ¸ðµ¨(Random-effects model)¿¡¼­ º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ¿Í ºñ º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ »çÀÌÀÇ OD Â÷ÀÌ°¡ ¾øÀ½À» ³ªÅ¸³Â´Ù(±³Â÷ºñ´Â 0.87, 95 % ½Å·Ú ±¸°£Àº 0.50-1.52, p = 0.49). 13,782 ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î 4°ÇÀÇ ¿¬±¸¿¡¼­ CSD¸¦ ÃøÁ¤ÇÏ¿´À¸¸ç, º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ¿Í ºñ º£Å¸ Â÷´ÜÁ¦ »ç¿ëÀÚ »çÀÌÀÇ CSD Â÷ÀÌ´Â °íÁ¤ È¿°ú ¸ðµ¨ (Fixed-effect model )À» »ç¿ëÇÏ¿© À¯ÀÇÇÏÁö ¾Ê¾Ò´Ù(OR 0.93, 95 % CI 0.82-1.06, p = 0.29). 3,923 ¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ 3 °ÇÀÇ ¿¬±¸°¡ Àç¹ß¿¡ ´ëÇÑ ºÐ¼®¿¡ Æ÷ÇԵǾú½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î º£Å¸ Â÷´ÜÁ¦´Â Àç¹ß·ü¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê¾ÒÀ½À» º¸°íÇÏ¿´´Ù (OR 0.70, 95 % CI 0.25-1.95, p = 0.49).

±Ù°Å¼öÁØ

Moderate

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2015 Medical Research Information Center (MedRIC) Editors


 

 


2018-03-07 ¿ÀÈÄ 12:57:43, Á¶È¸¼ö : 1734